Clinical Trial Update: Silymarin's Advantage on Graft Effectiveness [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update indicating enrollment by invitation for Silymarin to improve graft effectiveness in transplant patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection of Kidney Transplant
• Chronic Kidney Disease
• Graft Rejection
• Hypertension
• Posttransplant Diabetes Mellitus

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: University Hospital, Martin | Conditions: Posttransplant Diabetes Mellitus, Acute Graft Rejection | Phase 3 | Status: ENROLLING_BY_INVITATION